title: Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
abstract: Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily. They were evaluated with the Meares-Stamey test and the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at baseline and one week after therapy completion. Patients with microbiological eradication were evaluated again with the Meares-Stamey test 6 months after therapy completion. The microbiological eradication rate was 72.73% for prulifloxacin and 71.11% for levofloxacin (p=0.86) and the reduction in the NIH-CPSI was 10.75 and 10.73, respectively (p=0.98). Safety was comparable, with 18.18% adverse events for prulifloxacin and 22.22% for levofloxacin (p=0.79). Thus, a 4-week course of prulifloxacin 600 mg once daily is at least as effective and safe as levofloxacin 500 mg once daily in the treatment of CBP.
authors.affiliation: Department of Urology, University of Pisa, Pisa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Giannarini
authors.forename: A
authors.initials: A
authors.lastname: Mogorovich
authors.forename: F
authors.initials: F
authors.lastname: Valent
authors.forename: G
authors.initials: G
authors.lastname: Morelli
authors.forename: M
authors.initials: M
authors.lastname: De Maria
authors.forename: F
authors.initials: F
authors.lastname: Manassero
authors.forename: F
authors.initials: F
authors.lastname: Barbone
authors.forename: C
authors.initials: C
authors.lastname: Selli
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004148:Dioxolanes / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D064704:Levofloxacin; D015242:Ofloxacin; C074191:prulifloxacin